{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:56:11Z","timestamp":1761918971892},"reference-count":69,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.vaccine.2007.02.054","type":"journal-article","created":{"date-parts":[[2007,3,8]],"date-time":"2007-03-08T22:21:25Z","timestamp":1173392485000},"page":"3934-3945","source":"Crossref","is-referenced-by-count":13,"title":["Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model"],"prefix":"10.1016","volume":"25","author":[{"given":"Susanne","family":"El-Gogo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Staib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Meyr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Erfle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiko","family":"Adler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2007.02.054_bib1","doi-asserted-by":"crossref","first-page":"14560","DOI":"10.1073\/pnas.0404758101","article-title":"Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections","volume":"101","author":"Hilleman","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.vaccine.2007.02.054_bib2","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1567-5769(03)00016-X","article-title":"Old and new vaccine approaches","volume":"3","author":"Arnon","year":"2003","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"10.1016\/j.vaccine.2007.02.054_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nri1573","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection","volume":"5","author":"Rehermann","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2007.02.054_bib4","first-page":"468","article-title":"Isolation of five strains of herpesviruses from two species of free living small rodents","volume":"24","author":"Blaskovic","year":"1980","journal-title":"Acta Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2007.02.054_bib5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0966-842X(98)01306-7","article-title":"Murine gammaherpesvirus 68: a model for the study of gammaherpesvirus pathogenesis","volume":"6","author":"Simas","year":"1998","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.vaccine.2007.02.054_bib6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1369-5274(99)80071-X","article-title":"Host and viral genetics of chronic infection: a mouse model of gamma-herpesvirus pathogenesis","volume":"2","author":"Speck","year":"1999","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.vaccine.2007.02.054_bib7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0952-7915(99)80063-6","article-title":"Unraveling immunity to \u03b3-herpesviruses: a new model for understanding the role of immunity in chronic virus infection","volume":"11","author":"Virgin","year":"1999","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2007.02.054_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1089\/088282401753266747","article-title":"Vaccination against murine gamma-herpesvirus infection","volume":"14","author":"Woodland","year":"2001","journal-title":"Viral Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2007.02.054_bib9","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.coi.2004.05.002","article-title":"Immune evasion by gamma-herpesviruses","volume":"16","author":"Stevenson","year":"2004","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2007.02.054_bib10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1089\/vim.2005.18.445","article-title":"Immune mechanisms in murine gammaherpesvirus-68 infection","volume":"18","author":"Stevenson","year":"2005","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2007.02.054_bib11","series-title":"Fields virology","first-page":"2575","article-title":"Epstein\u2013Barr virus","author":"Rickinson","year":"2001"},{"key":"10.1016\/j.vaccine.2007.02.054_bib12","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1099\/0022-1317-79-7-1573","article-title":"Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8)","volume":"79","author":"Schulz","year":"1998","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2007.02.054_bib13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1098\/rstb.2000.0779","article-title":"Natural history of murine \u03b3-herpesvirus infection","volume":"356","author":"Nash","year":"2001","journal-title":"Phil Trans R Soc Lond B"},{"issue":"11","key":"10.1016\/j.vaccine.2007.02.054_bib14","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S1286-4579(02)01643-X","article-title":"A battle for survival: immune control and immune evasion in murine gamma-herpesvirus-68 infection","volume":"4","author":"Stevenson","year":"2002","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2007.02.054_bib15","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1099\/0022-1317-73-12-3275","article-title":"Murine gammaherpesvirus 68 establishes a latent infection in mouse B lymphocytes in vivo","volume":"73","author":"Sunil-Chandra","year":"1992","journal-title":"J Gen Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2007.02.054_bib16","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1128\/JVI.73.4.3273-3283.1999","article-title":"Macrophages are the major reservoir of latent murine gammaherpesvirus 68 in peritoneal cells","volume":"73","author":"Weck","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2007.02.054_bib17","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.4049\/jimmunol.165.2.1074","article-title":"Latent murine \u03b3-herpesvirus infection is established in activated B cells, dendritic cells, and macrophages","volume":"165","author":"Flano","year":"2000","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2007.02.054_bib18","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1084\/jem.187.12.1941","article-title":"Lung epithelial cells are a major site of murine gammaherpesvirus persistence","volume":"187","author":"Stewart","year":"1998","journal-title":"J Exp Med"},{"issue":"15","key":"10.1016\/j.vaccine.2007.02.054_bib19","doi-asserted-by":"crossref","first-page":"8310","DOI":"10.1128\/JVI.77.15.8310-8321.2003","article-title":"Long-term latent murine Gammaherpesvirus 68 infection is preferentially found within the surface immunoglobulin D-negative subset of splenic B cells in vivo","volume":"77","author":"Willer","year":"2003","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2007.02.054_bib20","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1084\/jem.20020890","article-title":"Gamma-herpesvirus latency is preferentially maintained in splenic germinal center and memory B cells","volume":"196","author":"Flano","year":"2002","journal-title":"J Exp Med"},{"issue":"13","key":"10.1016\/j.vaccine.2007.02.054_bib21","doi-asserted-by":"crossref","first-page":"7308","DOI":"10.1128\/JVI.77.13.7308-7318.2003","article-title":"Selective gene expression of latent murine gammaherpesvirus 68 in B lymphocytes","volume":"77","author":"Marques","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2007.02.054_bib22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1099\/0022-1317-77-4-627","article-title":"Murine gammaherpesvirus-induced splenomegaly: a critical role for CD4 T cells","volume":"77","author":"Usherwood","year":"1996","journal-title":"J Gen Virol"},{"issue":"15","key":"10.1016\/j.vaccine.2007.02.054_bib23","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1128\/JVI.74.15.6964-6974.2000","article-title":"Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome","volume":"74","author":"Adler","year":"2000","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2007.02.054_bib24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0966-842X(00)01747-9","article-title":"Infectious clones of herpesviruses: a new approach for understanding viral gene function","volume":"8","author":"Britt","year":"2000","journal-title":"Trends Microbiol"},{"issue":"47","key":"10.1016\/j.vaccine.2007.02.054_bib25","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1055\/s-0028-1108143","article-title":"MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)","volume":"99","author":"Stickl","year":"1974","journal-title":"Dtsch Med Wochenschr"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2007.02.054_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1439-0450.1976.tb01623.x","article-title":"TC marker of the attenuated vaccinia vaccide strain \u201cMVA\u201d in human cell cultures and protective immunization against orthopox diseases in animals","volume":"23","author":"Mayr","year":"1976","journal-title":"Zentralbl Veterinaermed B"},{"issue":"22","key":"10.1016\/j.vaccine.2007.02.054_bib27","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.vaccine.2007.02.054_bib28","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/viro.1997.8845","article-title":"Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line","volume":"238","author":"Carroll","year":"1997","journal-title":"Virology"},{"issue":"Pt 2","key":"10.1016\/j.vaccine.2007.02.054_bib29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1099\/0022-1317-79-2-347","article-title":"Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells","volume":"79","author":"Drexler","year":"1998","journal-title":"J Gen Virol"},{"issue":"Pt 5","key":"10.1016\/j.vaccine.2007.02.054_bib30","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J Gen Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2007.02.054_bib31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1568005033481123","article-title":"Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery","volume":"3","author":"Sutter","year":"2003","journal-title":"Curr Drug Targets Infect Disord"},{"issue":"1","key":"10.1016\/j.vaccine.2007.02.054_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0264-410X(03)00538-3","article-title":"Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals","volume":"22","author":"Cosma","year":"2003","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2007.02.054_bib33","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nm881","article-title":"Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans","volume":"9","author":"McConkey","year":"2003","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.vaccine.2007.02.054_bib34","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/10430340460745757","article-title":"Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus","volume":"15","author":"Corona Gutierrez","year":"2004","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.vaccine.2007.02.054_bib35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.vaccine.2005.08.041","article-title":"Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers","volume":"24","author":"Cebere","year":"2006","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2007.02.054_bib36","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-04-0602","article-title":"Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced. CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma","volume":"10","author":"Di Nicola","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.vaccine.2007.02.054_bib37","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1089\/104303403322319426","article-title":"Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial","volume":"14","author":"Di Nicola","year":"2003","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2007.02.054_bib38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/135965350501000212","article-title":"Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption","volume":"10","author":"Harrer","year":"2005","journal-title":"Antivir Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2007.02.054_bib39","doi-asserted-by":"crossref","first-page":"14567","DOI":"10.1073\/pnas.0404845101","article-title":"Gene-based vaccines and immunotherapeutics","volume":"101","author":"Liu","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.vaccine.2007.02.054_bib40","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1128","article-title":"Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans","volume":"10","author":"McShane","year":"2004","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.vaccine.2007.02.054_bib41","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1371\/journal.pmed.0010033","article-title":"A randomised, double-blind, controlled vaccine efficacy trial of DNA\/MVA ME-TRAP against malaria infection in Gambian adults","volume":"1","author":"Moorthy","year":"2004","journal-title":"PLoS Med"},{"issue":"8","key":"10.1016\/j.vaccine.2007.02.054_bib42","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1086\/378515","article-title":"Safety and immunogenicity of DNA\/modified vaccinia virus ankara malaria vaccination in African adults","volume":"188","author":"Moorthy","year":"2003","journal-title":"J Infect Dis"},{"issue":"Pt 4","key":"10.1016\/j.vaccine.2007.02.054_bib43","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1099\/vir.0.19701-0","article-title":"A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans","volume":"85","author":"Mwau","year":"2004","journal-title":"J Gen Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2007.02.054_bib44","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/jgm.397","article-title":"Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer","volume":"5","author":"Rochlitz","year":"2003","journal-title":"J Gene Med"},{"issue":"2","key":"10.1016\/j.vaccine.2007.02.054_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ijc.20569","article-title":"Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence","volume":"113","author":"Smith","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2007.02.054_bib46","doi-asserted-by":"crossref","first-page":"14759","DOI":"10.1073\/pnas.94.26.14759","article-title":"Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome","volume":"94","author":"Messerle","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.vaccine.2007.02.054_bib47","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2144\/00286st04","article-title":"Transient host range selection for genetic engineering of modified vaccinia virus Ankara","volume":"28","author":"Staib","year":"2000","journal-title":"Biotechniques"},{"key":"10.1016\/j.vaccine.2007.02.054_bib48","first-page":"77","article-title":"Construction and isolation of recombinant MVA","volume":"269","author":"Staib","year":"2004","journal-title":"Methods Mol Biol"},{"issue":"Pt 5","key":"10.1016\/j.vaccine.2007.02.054_bib49","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","article-title":"Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence","volume":"72","author":"Meyer","year":"1991","journal-title":"J Gen Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2007.02.054_bib50","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1128\/JVI.75.12.5692-5696.2001","article-title":"Virus reconstituted from infectious bacterial artificial chromosome (BAC)-cloned murine gammaherpesvirus 68 acquires wild-type properties in vivo only after excision of BAC vector sequences","volume":"75","author":"Adler","year":"2001","journal-title":"J Virol"},{"issue":"Pt 7","key":"10.1016\/j.vaccine.2007.02.054_bib51","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1099\/vir.0.80646-0","article-title":"Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara","volume":"86","author":"Staib","year":"2005","journal-title":"J Gen Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2007.02.054_bib52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/088282404322875467","article-title":"Mouse strain differences in the chemokine response to acute lung infection with a murine gammaherpesvirus","volume":"17","author":"Weinberg","year":"2004","journal-title":"Viral Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2007.02.054_bib53","first-page":"212","article-title":"Evaluation of real-time PCR data","volume":"18","author":"Vaerman","year":"2004","journal-title":"J Biol Regul Homeost Agents"},{"issue":"8","key":"10.1016\/j.vaccine.2007.02.054_bib54","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.1128\/JVI.71.8.5894-5904.1997","article-title":"Complete sequence and genomic analysis of murine gammaherpesvirus 68","volume":"71","author":"Virgin","year":"1997","journal-title":"J Virol"},{"issue":"15","key":"10.1016\/j.vaccine.2007.02.054_bib55","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/S0264-410X(02)00066-X","article-title":"Immunity, immunopathology and vaccines against HIV?","volume":"20","author":"Zinkernagel","year":"2002","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2007.02.054_bib56","doi-asserted-by":"crossref","first-page":"6827","DOI":"10.1128\/JVI.78.13.6827-6835.2004","article-title":"An optimized CD4 T-cell response can control productive and latent gammaherpesvirus infection","volume":"78","author":"Sparks-Thissen","year":"2004","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2007.02.054_bib57","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1128\/JVI.79.4.2573-2583.2005","article-title":"An optimized CD8+ T-cell response controls productive and latent gammaherpesvirus infection","volume":"79","author":"Braaten","year":"2005","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2007.02.054_bib58","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1371\/journal.pbio.0030120","article-title":"Gamma-herpesvirus latency requires T cell evasion during episome maintenance","volume":"3","author":"Bennett","year":"2005","journal-title":"PLoS Biol"},{"issue":"2","key":"10.1016\/j.vaccine.2007.02.054_bib59","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.4049\/jimmunol.172.2.1213","article-title":"Different functional capacities of latent and lytic antigen-specific CD8 T cells in murine gammaherpesvirus infection","volume":"172","author":"Obar","year":"2004","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2007.02.054_bib60","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1073\/pnas.040575197","article-title":"Postexposure vaccination massively increases the prevalence of \u03b3-herpesvirus-specific CD8+ T cells but confers minimal survival advantage on CD4-deficient mice","volume":"97","author":"Belz","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2007.02.054_bib61","doi-asserted-by":"crossref","first-page":"9281","DOI":"10.1073\/pnas.96.16.9281","article-title":"A gamma-herpesvirus sneaks through a CD8+ T cell response primed to a lytic-phase epitope","volume":"96","author":"Stevenson","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.vaccine.2007.02.054_bib62","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1128\/JVI.77.4.2522-2529.2003","article-title":"Effective vaccination against long-term gammaherpesvirus latency","volume":"77","author":"Tibbetts","year":"2003","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2007.02.054_bib63","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1073\/pnas.0307320101","article-title":"The limits of protection by \u201cmemory\u201d T cells in Ig\u2212\/\u2212 mice persistently infected with a gamma-herpesvirus","volume":"101","author":"Andreansky","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"10.1016\/j.vaccine.2007.02.054_bib64","doi-asserted-by":"crossref","first-page":"6836","DOI":"10.1128\/JVI.78.13.6836-6845.2004","article-title":"Critical role of CD4 T cells in an antibody-independent mechanism of vaccination against gammaherpesvirus latency","volume":"78","author":"McClellan","year":"2004","journal-title":"J Virol"},{"issue":"Pt 1","key":"10.1016\/j.vaccine.2007.02.054_bib65","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1099\/vir.0.81417-0","article-title":"Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy","volume":"87","author":"Clark","year":"2006","journal-title":"J Gen Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2007.02.054_bib66","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.70.6.3741-3752.1996","article-title":"Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara","volume":"70","author":"Hirsch","year":"1996","journal-title":"J Virol"},{"issue":"14","key":"10.1016\/j.vaccine.2007.02.054_bib67","doi-asserted-by":"crossref","first-page":"7187","DOI":"10.1128\/JVI.76.14.7187-7202.2002","volume":"76","author":"Horton","year":"2002","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2007.02.054_bib68","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1365-2249.2005.02919.x","article-title":"Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection","volume":"142","author":"Encke","year":"2005","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2007.02.054_bib69","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jmv.20264","article-title":"Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein","volume":"75","author":"Gehring","year":"2005","journal-title":"J Med Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07002368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07002368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T14:46:47Z","timestamp":1707662807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X07002368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":69,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0264410X07002368"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2007.02.054","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}